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Renal interactions between norepinephrine and calcium antagonists.
The combined action of norepinephrine and calcium antagonists on the
glomerular filtration rate (GFR) of isolated rat kidneys perfused at a
constant pressure of 105 mm Hg was studied. Norepinephrine, 74 9
ng/ml (mean SEM), increased the renal vascular resistance (RVR) by
50% and GFR declined by 88% (P < 0.001). The subsequent addition of
either diltiazem or verapamil (5 M) returned RVR nearly to control and
increased the GFR by an average of 86% over control (P = 0.007).
Diltiazem or verapamil alone had little effect on RVR or GFR. Norepi-
nephrine (20 ng/ml) did not affect RVR or GFR. In the presence of
diltiazem, norepinephrine (20 ng/ml) again did not affect RVR but
increased GFR by 58% (P = 0.003). With a low-calcium perfusate
containing 0.4 mr'i total calcium, norepinephrine (90 nglml) did not
affect RVR or GFR. Increasing perfusate norepinephrine to 236 8
nglml elicited a 50% increase in RVR, and GFR decreased by 95% (P <
0.001). The subsequent addition of verapamil increased GFR to 2.8
times the original baseline value (P = 0.011) and restored RVR to
control levels. These data suggest that diltiazem and verapamil block
the vasoconstrictor action of norepinephrine on afferent arterioles
selectively. Renal vascular sensitivity to norepinephrine decreases
markedly either when the extracellular calcium concentration is re-
duced or in the presence of a calcium antagonist. However, a low-
calcium perfusate does not mimic the property of calcium antagonists to
facilitate an increase in GFR in the presence of norepinephrine.
Interactions rénales entre Ia noradrénaline et les antagonistes calciques.
Nous avons étudié l'action combinée de Ia noradrénaline et des
antagonistes du calcium sur le debit de filtration glomerulaire (GFR) de
reins de rats isolés et perfuses a une pression constante de 105 mm Hg.
La noradrénaline, 74 9 ng/ml (moyenne SCM) a augmenté la
résistance vasculaire rénale (RVR) de 50% et GFR a décliné de 88% (P
< 0,001). L'addition ultérieure de diltiazem ou de vérapamil (5 1M) a
ramenC RVR presqu'au contrOle et a augmenté GFR a 86% au dessus du
contrôle en moyene (P = 0,007). Le diltiazem ou Ic verapamil seuls
avaient peu d'effet sur RVR ou GFR. La noradrénaline (20 ng/ml) n'a
pas affecté RVR ou GFR. En presence de diltiazem, Ia noradrdnaline
(20 ng/ml) une fois encore n'a pas modiflé RVR, mais a augmenté GFR
de 58% (P = 0,003). Avec on perfusat pauvre en calcium contenant 0,4
mM de calcium total, Ia noradrénaline (90 ng/ml) n'a pas affecté RVR ou
GFR. L'augmentation de Ia noradrénaline dans le perfusat a 236 8
ng/ml a entrainé une élévation de 50% de RVR, et GFR a diminuC de
95% (P < 0,001). L'addition ultérieure de vérapamil a augmente GFR a
2,8 fois Ia valeur basale originelle (P = 0,011) eta restauré RVR a ses
niveaux contrôles. Ces données suggèrent que Ic diltiazem et le
vérapamil bloquent l'action vasoconstrictrice de Ia noradrénaline
sélectivement dans les arterioles afférentes. La sensibilité vasculaire
rénale a Ia noradrénaline diminue considCrablement soit lorsque Ia
concentration calcique extracellullaire est réduite, soit en presence d'un
antagoniste du calcium. Néanmoins, un perfusat pauvre en calcium ne
reproduit pas Ia propriété des antagonistes calciques de faciliter une
élévation de GFR en presence de noradrénaline.
In previous work we used an isolated perfused rat kidney and
found that high-frequency renal nerve stimulation was of suf-
ficient intensity to increase the renal vascular resistance (RVR)
by 50% also markedly decreasing the glomerular filtration rate
(GFR), urine flow (V), and sodium excretion (UNaY) [1]. The
addition of the calcium channel-blocking agents, verapamil or
diltiazem, returned the GFR, V, and UNaV to control values,
and nearly reversed the increase in RYR. We then employed
the adrenergic mediator, norepinephrine, to determine if it
elicited actions similar to nerve stimulation. At concentrations
sufficient to increase RVR similarly, norepinephrine also de-
creased GFR, V, and UNaV—changes which again were re-
versed by verapamil. Of interest, V and UNaV significantly
exceeded control values when both norepinephrine and
verapamil were present. Although not statistically significant,
GFR exceeded the original control values by substantial mar-
gins in four out of six studies.
Those results suggested that a combination of norepinephrine
and a calcium channel blocker might elicit an increase in GFR
under appropriate conditions. Because our previous data also
indicated that a low calcium concentration in the perfusate
abrogated all the renal hemodynamic effects of nerve stimula-
tion [1], it seemed likely that decreasing the perfusate calcium
might lower the renal vascular sensitivity to norepinephrine.
The present experiments were designed first to examine the
possibility that, in the presence of calcium antagonists, norepi-
nephrine can increase the GFR. Second, we examined the effect
of changes in extracellular calcium on the renal vascular actions
of norepinephrine in order to determine whether a low extra-
cellular calcium concentration can mimic the action of calcium
channel blockers.
Methods
We studied kidneys isolated from 47 normal male Sprague-
Dawley rats weighing 350 to 400 g. Kidney isolation and
perfusion with a modified Krebs-Henseleit solution were done
as described previously [2]. We utilized a perfusion technique
and apparatus very similar to that of Bowman [3], but employ-
ing a Masterfiex perfusion pump (Model 7565, Cole Parmer
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Table 1. Time control experiments in the presence and absence of norepinephrinea
C El E2
RVR, mm Hg/mlmin'
No experimental manipulation (N 5) 2.8 (±0.1) 2.8 (±0.1) 2.9 (±0.1)
Norepinephrine between "C" and "El" (N = 5) 2.5 (±0.1) 4.0 (±0.2)" 3.9 (±0.4)"
P (between groups) 0.02 < 0.001 0.01
GFR, mi/mm
No experimental manipulation (N = 5) 0.71 (±0.07) 0.66 (±0.07) 0.68 (±0.07)
Norepinephrine between "C" and "El" (N = 5) 0.68 (±0.06) 0.04 (±0.01)" 0.18 (±0.08)"
P (between groups) NS <0.001 0.001
Abbreviations: RVR, renal vascular resistance; GFR, glomerular filtration rate; C, corresponds to control phase; El and E2 correspond
temporally to two experimental phases following the control phase.
aValues are mean (± SEM).
bp < 0.001 compared to control (paired testing).
"P < 0.005 compared to control. Otherwise, comparisons not significant (NS), with P> 0.05.
Instrument Company, Chicago, Illinois). After flushing and
isolation without ischemia, kidneys were perfused at 37°C with
a recirculating oxygenated albumin-containing solution at a
perfusion pressure of 105 mm Hg. Bovine serum albumin
fraction V (Pentex Miles, Kankakee, Illinois) had been dialyzed
previously for 72 to 96 hr [4]. Perfusate oxygenation was
accomplished by equilibration with 95% 02—5% C02, resulting
in a stable pH at 7.40—7.42.
The electrolyte composition of normal perfusate included (in
mM): sodium 135, potassium 4, bicarbonate 22, chloride 110,
calcium 2.0, and magnesium 0.75. Perfusate also contained
glucose and inulin, each at 100 mg/dl, and albumin at 6.5 to 7.0
g/dl. L-isomers of the following amino acids (Sigma Chemical,
St. Louis, Missouri) were added (in mM): glutamate 0.50, serine
1.00, asparagine 0.20, cysteine 0.50, aspartate 0.20, alanine
2.00, glycine 2.30, and glutamine 2.00. Other amino acids were
added as 5.5% Travasol® (Travenol Laboratories, Deerfield,
Illinois) in the following final perfusate concentrations (in mM):
leucine 0.43, phenylalanine 0.34, methionine 0.35, lysine 0.36,
isoleucine 0.33, valine, 0.35, histidine 0.25, threonine 0.32,
tryptophan 0.08, arginine 0.54, proline 0.33, tyrosine 0.02, and
alanine 0.26 (total alanine, 2.26). This amino acid combination
has been reported to stabilize isolated rat kidney function [5].
The hydraulic pressure of the perfusion system and the
perfusate flow rate were monitored continuously. In order to
determine the RVR accurately, the decrease in hydraulic pres-
sure along each cannulating needle had been determined previ-
ously in preliminary calibration studies, allowing calculation of
the true renal perfusion pressure distal to the cannula tip 121.
After an initial 20 to 30 mm of perfusion, urine and perfusate
specimens were obtained for two control periods of 5 to 10 mm
each. When subsequent pharmacologic maneuvers produced a
change in RVR, a constant perfusion pressure of 105 mm Hg
distal to the cannula tip was maintained by regulating the
perfusate flow rate appropriately, Vascular resistance was
allowed to stabilize (usually over an interval of less than 5 mm)
before specimens were obtained for individual experimental
periods of 5 to 8 mm duration. This limited the duration of the
experiments to a maximum of 1 hr in addition to the initial
equilibration interval.
Urine volumes were estimated gravimetrically. Inulin was
analyzed by an automated resorcinol method [6], sodium was
measured by flame photometry, and total calcium was mea-
sured by atomic absorption spectrophotometry. The inulin
clearance was used as an estimate of the GFR. RVR was
computed as the renal perfusion pressure divided by perfusate
flow.
Verapamil was a gift from the Knoll Pharmaceutical Com-
pany, Whippany, New Jersey, and diltiazem was a gift from
Marion Laboratories, Kansas City, Missouri. Verapamil,
diltiazem, and norepinephrine (Parke-Davis, Morris Plains,
New Jersey) were dissolved directly in perfusate.
The data were not factored by kidney weights because
factoring did not decrease the variances significantly. Also a
report has indicated that the wet weight of an isolated perfused
rat kidney varies inversely with the perfusate albumin concen-
tration [7]. The level of statistical significance was set at P <
0.05. Statistical comparisons of values from different phases
within the same study were done by the paired t test when
analysis of variance indicated that significant paired differences
existed. The significance of differences between different ex-
perimental groups was determined by an analysis of variance
and unpaired t testing, the latter utilizing the Bonferroni modi-
fication for simultaneous multiple comparisons when appropri-
ate [8, 9]. Values are expressed as means SE.
Results
In order to assess the extent of spontaneous variation in
function of the isolated kidney preparation during the time
course of the studies, two types of time-control experiments
were done (Table 1). In the first type, no experimental manipu-
lations were done during a control and two experimental
phases. In the second type, sufficient norepinephrine was added
following the control phase to increase RVR by 50%. This
required norepinephrine concentrations of 50 to 110 ng/ml
(mean, 75 8 ng/ml). Norepinephrine elicited a 94% decrease
in GFR (Table 1). During the course of these experiments, there
was no fall-off in RVR or significant recovery of GFR. In the
studies without norepinephrine, no significant changes in RVR
or GFR occurred.
We again increased RVR by 50% over control values by
adding norepinephrine in perfusate at concentrations of 45 to
115 ng/ml (mean, 74 9 ng/ml; Fig. 1). Norepinephrine
increased the RVR by 1.5 0.2 mm Hg/m1 min' (mean
SEM) and again decreased the GFR sharply from 0.65 0.08 to
0.08 0.02 mi/mm (P < 0.001). Urine flow (V) and sodium
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Fig. 1. Antagonism of norepinephrine in the isolated perfused kidney by
verapamil (—., N = 5) or diltiazem (o--.o, N = 5), 5 M. Norepi-
nephrine concentrations of 45 to 115 ng/ml were needed in order to
increase the RVR by 50%. Abbreviations: C, control; NE, norepineph-
rine; CA, calcium antagonist (verapamil or diltiazem). P values are
results of paired comparisons with the control phase. Lack of a P value
indicates that comparison was not statistically significant (P > 0.05).
excretion (UNaV) also decreased (P = 0.023 and 0.028, respec-
tively). Either verapamil or diltiazem, added at a perfusate
concentration of 5 LM, rapidly reversed the change in RVR
nearly to control values (2.7 0.1 compared to a control of 2.5
0.1 mm Hg/miS min'; P = 0.31), and increased the GFR, V
and UNaV to values significantly greater than control (P =
0.007, P < 0.001, and P 0.008, respectively). For each of the
verapamil and diltiazem subsets, GFR increased in four of the
five experiments when calcium antagonists were present with
norepinephrine. In the verapamil studies, the final GFR was
0.93 0.23 mi/mm compared to a control value of 0.54 0.10
(P = 0.051); in the diltiazem studies, the final GFR was 1.50
0.24 mi/mm compared to a control value of 0.76 0.11 (P =
0.028).
We examined the direct effects of verapamil or diltiazem
alone, at concentrations of 1 to 10 ILM, in dose-response
experiments (Fig. 2). Diltiazem did not affect RVR, GFR, V, or
UNaV significantly over this concentration range. Verapamil, in
contrast, produced a slight but statistically significant decrease
in RVR at all three concentrations (P < 0.03). In addition,
verapamil was mildly diuretic and natriuretic at 10 M (P <
0.03). Thus, diltiazem and verapamil elicited only modest
changes in renal function when administered alone. At each
calcium antagonist concentration, the values of RVR, GFR, V,
and UNaV did not differ significantly between the two agents.
Preliminary experiments indicated that 20 ng/mI was the
maximum norepinephrine concentration that consistently failed
to increase RVR. At this concentration, norepinephrine also
produced no significant changes in RVR, GFR, V, or UNaV.
The addition of norepinephrine, 20 ng/ml, to perfusate contain-
ing 5 .rM diltiazem (Fig. 3) also did not significantly affect RVR,
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Fig. 2. Dose-response relationships of verapamil (.—., N = 5) and
diltiazem (0-- -0, N 5). "P' values reflect significant paired compari-
sons with "zero-concentration" control phases. Significant changes
occurred only for verapamil (V). At each drug concentration, values for
verapamil (N = 5) and diltiazem (N = 5) did not differ significantly
from one another. Means and sE are depicted.
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Fig. 3. Studies with diltiazem (DIL) pretreatment (N = 6). In the
presence of diltiazem (5 /LM), norepinephrine concentrations of 20 ng/ml
produced an increase in GFR without affecting RVR. Norepinephrine,
90 ng/ml, increased RVR and returned GFR to control levels in the
presence of diltiazem. Values in parentheses are norepinephrine con-
centrations in ng/ml.
but did increase the GFR from 0.98 0.07 to 1.54 0.18
ml/min (P = 0.006). Concomitantly, V increased from 24 6 to
42 11 pi/min(P = 0.006), and UNaV increased from 1.8 0.7
to 2.5 0.6 Eq/min (P = 0.021). Increasing perfusate
norepinephrine to 90 ng/ml lowered the GFR to 0.85 0.18
mi/mm, a value similar to control. This concentration of nor-
epinephrine also increased RVR from 2.68 0.05 to 3.22
L
OIL
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Fig. 4. Experiments using a low-calcium (0.4 mm) perfusate (N = 5).
The preparation was nearly refractory to a norepinephrine concentra-
tion of 90 ng/ml, but responded to higher concentrations (220 to 260
ng/ml) with a 50% increase in RVR. With the addition of verapamil
(VER), 5 /LM, RVR returned to control levels and GFR increased by
182% over control values. Parentheses contain norepinephrine concen-
trations in ng/ml.
0.14 mm Hg/mi min (P = 0.003). V remained increased (P
= 0.023) and sodium excretion decreased to 1.6 0.3
iEq/min, a value similar to control. Note that the norepineph-
rifle concentration of 90 mg/mi was considerably greater than
the mean concentration required in the studies depicted in
Figure 1 (74 9 ng/ml).
Continuing with the same diltiazem pretreatment experi-
ments (but not shown in Fig. 3), we added sufficient norepi-
nephrine to increase the RVR by 50% over control. This
required norepinephrine concentrations of 130 to 200 ng/ml
(mean, 170 13 ng/ml) in the presence of diltiazem. RVR
increased to an average of 4.1 0.1 mm Hg/mi. min1 (P =
0.003), and GFR fell to 0.08 0.02 mI/mm (P < 0.001), a value
identical to the GFR obtained with 45 to 115 ng/ml norepineph-
rifle in the absence of calcium antagonists (Fig. 1). V and UNaV
also decreased markedly.
Because preliminary studies had suggested that norepineph-
rifle, 90 ng/ml, did not increase RVR when perfusate contained
0.4 m total calcium (normal perfusate calcium, 2.0 mM), we
utilized a low-calcium perfusate and different concentrations of
norepinephrine (Fig. 4). The addition of norepinephrine 90
ng/ml to low-calcium perfusate did not affect RVR, GFR, or
UNaV significantly. V increased slightly from 19 5 to 31 6
p11mm (P = 0.044). We then added sufficient norepinephrine to
increase RVR by 50% over control. This required norepineph-
rifle concentrations of 220 to 260 ng/ml (mean, 236 8 ng/ml) to
increaseRVRfrom2.6 0.lto3.6 0.1 mmHg/ml min(P
<0.001). Concomitantly, GFR fell to 0.03 0.02 mI/mm (P <
0.001), a value similar to the GFR obtained when 45 to 115
ng/ml norepinephrine was added to a normal perfusate (Fig. 1).
V and UNaV also fell to values significantly less than control (P
0.025). The subsequent addition of verapamil, 5 ELM, reduced
RVR to 2.6 0.1 mm Hg/mi min', a value identical to the
original control resistance (Fig. 5). Concomitantly GFR in-
creased to 1.81 0.35 mI/mm a value significantly greater than
any preceding one (P = 0.011). V increased to 76 9 p1/mm (P
= 0.002) and UNaV increased to 1.9 0.4 Eq/min a value
similar to control. Therefore, unlike experiments employing a
normal-calcium perfusate (Fig. 3), high concentrations of nor-
epinephrine increased the GFR in the presence of a calcium
antagonist when the extracellular calcium concentration was
reduced.
Discussion
The circumstances under which norepinephrine and calcium
antagonists increased the GFR are summarized in Figure 5.
Both norepinephrine and a calcium antagonist were needed.
GFR never increased significantly with either type of agent
alone. Although diltiazem [101 and verapamil [111 have been
reported to at least partially reverse norepinephrine-induced
vasoconstriction and GFR reductions in the isolated rat kidney,
increases in GFR to supracontrol values have not been re-
ported. The action of these calcium channel blockers to in-
crease the GFR in the presence of norepinephrine was not an
"overshoot" phenomenon secondary to a putative postische-
mic hyperemia because the effect was reproduced with concen-
trations of norepinephrine insufficient to affect RVR or perfus-
ate flow. Changes in V and UNaV usually occurred in parallel
with changes in GFR. Although norepinephrine can increase
sodium absorption by the isolated rabbit proximal convoluted
tubule [12—151, a direct effect of norepinephrine on whole-
kidney sodium reabsorption could not be documented in the
present studies. We have not presented sodium reabsorption
data explicitly, but any significant increases in sodium reab-
sorption always accompanied at least slightly larger increases in
filtered sodium secondary to substantial increases in the GFR in
the presence of norepinephrine and calcium antagonists. Ac-
cordingly, changes in sodium reabsorption could be attributable
to changes in the filtered load in these experiments.
The addition of calcium channel blockers to perfusate mark-
edly decreased the sensitivity of the isolated kidney vasculature
to norepinephrine. The actions of calcium channel-blocking
agents are often considered to reflect their ability to prevent
increases in cytosol ionized calcium [16—181. This has been
postulated to occur through a variety of mechanisms, including
the prevention of extracellular calcium entry, diminished cell
calcium mobilization from membrane stores, and perhaps an
increase in calcium extrusion from cells [18—201. In addition,
verapamil (but not diltiazem) can bind competitively to two
subtypes of alpha adrenergic receptors [21]. Similarly to the
calcium channel blockers, a low-calcium perfusate markedly
decreased renal vascular sensitivity to norepinephrine. Thus,
the concentration of extracellular calcium appears to be critical
in determining the sensitivity of the renal vasculature to nor-
epinephrine. We have not determined the changes in sensitivity
to norepinephrine over a wide range of extracellular calcium
concentrations. However, the low-calcium perfusate we em-
ployed contains the minimum concentration of calcium consist-
ent with the maintenance of good isolated kidney function in
our experience.
The fact that decreasing the extracellular calcium concentra-
tion reduces norepinephrine sensitivity, similarly to the calcium
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Fig. 5. Summary of a/I conditions leading to an
increased GFR. GFR and RVR are plotted on
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Recently, Edwards [27] reported that norepinephrine elicited
vasoconstriction of both the afferent and efferent arterioles, as
determined by direct visual observations. Norepinephrine dif-
fered from angiotensin II, in that the latter constricted only
efferent arterioles [271. In our experiments, verapamil and
diltiazem may have converted the action of norepinephrine to
efferent arteriolar selectivity. Verapamil and diltiazem share the
property of blocking selectively vascular alpha-2 adrenoceptor
mediated responses to agonists [28—30]. Speculatively, depend-
ing on the relative afferent and efferent arteriolar distributions
of alpha-I and alpha-2 adrenoceptor subtypes, verapamil and
diltiazem could have interfered selectively with the
vasoconstrictor action of norepinephrine on the afferent
arteriole while leaving intact its action on the efferent arteriole.
The expected result would be an increase in GFR.
It is unlikely that angiotensin II mediated the increases in
GFR accompanying norepinephrine and calcium antagonists
because of the absence of angiotensinogen from the perfusate.
Cohen et al have reported that a sixfold increase in renin release
by the isolated rat kidney, during perfusion with a solution
containing hyperoncotic albumin, is not accompanied by any
change in RVR [31]. Also, unlike the case with angiotensin II
[2], increases in GFR in our present studies were not ac-
companied by large increases in RVR. It appears that either the
angiotensins are not formed by this preparation in the absence
of added angiotensinogen, or that they are formed in amounts
insufficient to affect the renal circulation substantially.
Because GFR increased, the calcium antagonists may have
blocked a putative action of norepinephrine on the glomerular
mesangium [32], even though a direct action of norepinephrine
on the mesangium to decrease the glomerular ultrafiltration
coefficient has not been documented. Both afferent and efferent
arteriolar vasoconstriction have been attributed to norepineph-
rine [27, 33, 34]. In addition to an alpha adrenergic action
promoting vasoconstriction, norepinephrine also elicits a beta
channel blockers, suggests that actions of the latter compounds
at or near membrane calcium channels is critical in our experi-
mental setting. On the other hand, a reduction in the perfusate
calcium did not substitute for the calcium antagonists with
regard to the effect of norepinephrine on GFR in their presence.
In fact, GFR nearly trebled when verapamil and high concentra-
tions of norepinephrine were added to the low-calcium perfus-
ate (Figs. 4 and 5). However, even with the low-calcium
perfusate, an ionized calcium concentration gradient exceeding
2000-fold between perfusate and smooth muscle cytosol would
be expected [22—24].
In the experimental phases with increased GFR values,
perfusate flow was not markedly different from control values
because RVR remained nearly constant at a constant perfusion
pressure. Therefore, the filtration fraction increased approxi-
mately in proportion to the GFR. In the living animal, a 50 to
100% increase in the filtration fraction is accompanied by a
parallel rise in the glomerular capillary albumin concentration
and increasing capillary oncotic pressure, to the point of
attaining filtration equilibrium prior to reaching the efferent
arteriole [25]. One advantage in using the isolated perfused
kidney lies in the fact that changes in glomerular capillary
albumin concentrations are negligible, even during wide varia-
tions in the GFR. This is a consequence of the high perfusate
flow rates needed to maintain oxygenation and a perfusion
pressure of 105 mm Hg with a cell-free perfusate [26]. Glomer-
ular filtration proceeds virtually unopposed by constantly in-
creasing capillary albumin concentrations. Thus the isolated
kidney preparation might manifest increased responses to the
combined glomerular actions of norepinephrine and calcium
antagonists, as compared to what might be expected in the
intact animal. Others have cautioned, with good reason we
believe, that results from studies dealing with circulatory altera-
tions in isolated kidneys cannot be applied directly to the intact
animal [26].
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adrenergic glomerular action which results in cyclic nucleotide
generation and activation of the renin-angiotensin system [351.
As discussed above, the latter is unlikely in the present studies.
If naturally occurring antagonists of calcium or norepineph-
rine circulate in the intact animal, these could ameliorate
ischemia and reductions in glomerular filtration during states of
intense adrenergic discharge. The existence and identity of
putative natural antagonists of calcium-mediated actions of
norepinephrine applicable to our experimental situation are
unclear. Reasonable candidates would be the vasodilator
prostanoids [36] and kinins [371 in that these are known modula-
tors of the effects of renal adrenergic transmission.
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